ARL6IP5 and lung carcinoma: To test whether JAC4 could downregulate EGFR in lung-cancer cells, upon JAC4 treatment, immunoblotting analysis was carried out and showed that the protein expression of JWA was increased, whereas the expression of EGFR was decreased in dose- and time-dependent manners; moreover, the downstream of EGFR-related markers (P-AKT and P-STAT3) were synchronously suppressed (Figure 3B,C and Figure S4A,B).